SRC and breast carcinoma: To this end, we employed gene signatures representative of E2F, PI3K, Myc, β-catenin, Src, and Ras pathway activation, as well as signatures of response to other commonly used cytotoxic agents in breast cancer (docetaxel, etoposide, vinorelbine and cisplatin), in the cohort of 133 patients.